Indonesia’s BPOM Approves Russian Covid-19 Medication
Indonesia is taking further steps to contain Covid-19, as the Food and Drug Agency or BPOM “has issued the emergency use authorization or EUA for Avifavir a Russian-made Covid-19 medication,” said the Agency’s spokesperson Lucia Rizka.
She added that the medication, which is manufactured by the ChemRar pharmaceutical group and the Russian Direct Investment [RDIF] group. BPOM registered Avivafir, which is based on favipravir, a Japanese experimental antiviral drug that is used to treat flu symptoms.
RDIF Director Kirill Dmitriev hailed BPOM’s decision.
“The Indonesian [medical authorities] have expressed their confidence in Avifavir, as they registered the medication without further clinical tests,” he said, as quoted by the Russia Beyond the Headlines [RBTH] media outlet last Tuesday.
“Avifavir has a very high efficiency [rate], as it can significantly reduce the [patient’s] recovery time. In doing so, it can ease the burden of medical facilities.”
In its EUA, BPOM said Avifavir is designated for people from the ages of 18 and up “who are experiencing mild to moderate Covid-19 symptoms. "
Russia has supplied Avifavir to 15 countries, including Indonesia, since June 2020. Moscow said the medication showed efficacy rates of 80 percent or more. Avifavir’s creators claimed that regular consumption of the medication can eliminate the Covid-19 virus in four days.